Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) area. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.
First patients enrolled in phase III clinical trials of elobixibat
Albireo receives 3.5 MSEK in support from VINNOVA
Go to news archive
JP Morgan, San Francisco, Jan 2014
DDW, Chicago, May 2014